Deep Vein Thrombosis (DVT) In Thrombophilia: Prevalence And Prevention
Published on: July 31, 2026
Deep Vein Thrombosis (DVT) In Thrombophilia Prevalence And Prevention featured image
  • Article author photo

    Adeline Sever

    MSc Experimental Pharmacology and Therapeutics (Neuropharmacology), University College London

Overview

Deep vein thrombosis (DVT) is a condition where a blood clot (thrombus) develops within the deep veins of the body, partially or fully blocking blood flow through the vein and causing leg pain and swelling. This most commonly occurs within the leg but can also develop in other parts of the body. This can lead to further complications, such as pulmonary embolism (PE), when a blood clot travels (embolus) and becomes lodged in the blood vessels of the lungs. One of the causes of DVT is a condition known as thrombophilia.

Thrombophilia is a blood disorder that increases the likelihood of blood clotting in the veins and arteries, which can lead to DVT, heart attack, stroke, or damage to the internal organs. This condition can be either inherited (genetic) or acquired later in life.

This article will explore the relationship between DVT and thrombophilia, its prevalence, and prevention strategies.

Types of thrombophilia

Both types of thrombophilia can contribute to the formation and progression of DVT by altering the body's normal blood clotting mechanisms.

Inherited thrombophilia

This type of thrombophilia is inherited from one or both parents who carry the gene. Thrombophilia arises when a genetic mutation causes the blood clot-forming proteins to function abnormally or when insufficient amounts of regulatory proteins are produced to prevent excessive clotting. There are several types of genetic thrombophilia, such as:

  • Factor V Leiden thrombophilia: the most common type, caused by a mutation in the F5 gene, which controls a protein called factor V and alters its structure. This protein assists with blood clotting after injury; when it functions abnormally, it increases the risk of blood clots
  • Prothrombin thrombophilia: mutations to the prothrombin gene (G20210A) increase the likelihood of developing abnormal clots in the veins. The body produces more prothrombin protein than is needed for clot formation, leading to a higher clotting tendency
  • Protein C deficiency: a disorder in which blood clots excessively. Protein C is a natural anticoagulant that inhibits clotting; insufficient levels result in excessive clot formation
  • Protein S deficiency: a disorder in which blood clots too easily. Protein S regulates the proteins responsible for clot formation; a deficiency results in excessive clotting
  • Protein Z deficiency: a disorder in which the body does not produce sufficient amounts of protein Z, which is required to regulate blood clotting, thereby increasing clot formation. Pregnancy complications such as miscarriage are also more likely to occur with this disorder
  • Antithrombin deficiency: a disorder characterised by a reduced number of natural anticoagulant proteins, which leads to a higher risk of abnormal blood clotting

Acquired thrombophilia

This type of thrombophilia is more common than the inherited type and can arise from several medical conditions, such as:

  • Antiphospholipid syndrome (APS): the most common and aggressive form of acquired thrombophilia. This autoimmune disease increases the risk of blood clotting and pregnancy complications, which can lead to severe outcomes such as strokes and miscarriages
  • Disseminated intravascular coagulation (DIC): a blood clotting disorder that occurs following illnesses such as sepsis or cancer
  • Systemic conditions: including kidney or liver disease, HIV, hepatitis, and cancer
  • Hormonal influences: such as oral contraceptives (particularly combined oestrogen and progestogen preparations) and hormone therapies

You are also more likely to acquire thrombophilia through other risk factors, such as:

  • Being pregnant or giving birth
  • Having miscarriages
  • Being overweight or obese
  • Smoking
  • Remaining immobile for a prolonged period, such as during a long-haul flight
  • Having had a blood clot previously
  • Having a family history of blood clots
  • Being over the age of 60

Symptoms of DVT in thrombophilia

Thrombophilia can lead to complications such as DVT. If you have DVT, you may not experience any symptoms in mild cases, but the following may be present in more severe cases. Symptoms most commonly affect the leg or, occasionally, the arm, and can include:

  • Swelling
  • Throbbing pain or tenderness, usually when standing or walking
  • Skin that is warm to the touch at the site of swelling or pain
  • Skin that is red or discoloured at the site of swelling or pain
  • Swollen, sore, and firm veins visible near the surface of the skin

If the blood vessels supplying the abdomen or brain are affected, this can cause abdominal pain or severe headaches and seizures, respectively.

In some cases, symptoms only present when DVT progresses to PE, in which the clot moves from the leg or arm to the lungs. Symptoms of PE include:

  • Chest pain
  • Shortness of breath or rapid breathing
  • Rapid heart rate
  • Lightheadedness
  • Fainting
  • Coughing up blood

If left untreated, DVT can progress to a pulmonary embolism, which is life-threatening. Post-thrombotic syndrome (PTS) is a complication that may arise following DVT, characterised by chronic pain and swelling in the affected limb.

Prevalence of DVT in thrombophilia

DVT is the third most common vascular disease after stroke and heart attack, with approximately 1 to 3 in every 1,000 adults developing DVT each year in the United States, and up to 300,000 dying from the condition annually. DVT is more common in those over 60 years old but can also occur in children and adolescents. Over half of all cases of DVT occur after a hospital stay involving prolonged immobility.

The prevalence of DVT in individuals with thrombophilia depends on whether it is genetic and the specific mutation involved, or acquired and the medical condition that causes it.

Genetic thrombophilia

  • Factor V Leiden mutation: present in up to 1 to 5 people who develop DVT. Prevalence varies by ethnicity: approximately 1 in 20 white individuals, 1 in 50 Black or Hispanic individuals, and 1 in 100 Asian individuals carry this mutation. However, 9 out of 10 people with this type of thrombophilia never develop abnormal blood clots
  • Prothrombin gene mutation: present in 1 in every 50 white people in Europe and North America, and approximately 1 in 250 Black individuals in North America. The risk of developing DVT from this mutation is approximately 2% to 3%
  • Protein C, S, and Z mutations: considerably rarer, affecting fewer than 1% of the population. However, these conditions significantly increase the risk of DVT by 2- to 11-fold, affecting approximately 1 in every 100 to 500 individuals
  • Antithrombin deficiency: very rare, affecting 1 in every 2,000 to 3,000 people. However, 80% of individuals with this type of thrombophilia will have experienced at least one blood clot by the age of 50, indicating a significantly elevated risk of DVT

Acquired thrombophilia

  • Antiphospholipid syndrome (APS): accounts for 20% to 30% of DVT cases

Prevention strategies for DVT in thrombophilia

If you suspect you have a blood clot or know you are at risk, you should arrange an appointment with your healthcare provider. DVT and thrombophilia can be diagnosed via angiogram or venogram, ultrasound, MRI, or CT scan, which examine the veins and scan the body for the presence of blood clots. Once diagnosed, prevention strategies such as medical treatment and lifestyle changes can be used to manage the condition.

Medical treatment

  • Anticoagulants: the main treatment for DVT. These are blood-thinning drugs that make it harder for the blood to clot or prevent existing clots from growing larger. Options include warfarin and factor Xa inhibitors, taken orally for at least 3 to 6 months in milder cases, or lifelong in severe cases. Heparin may be used in individuals who develop DVT during pregnancy, administered via intravenous (IV) drip or subcutaneous injection throughout pregnancy and for six weeks after childbirth
  • Surgical intervention: if anticoagulants are contraindicated or ineffective, surgery may be required to remove the blood clot. A surgeon may also insert an inferior vena cava (IVC) filter to prevent clots from travelling to the lungs and causing a PE

Lifestyle changes

  • Regular exercise: staying active through regular physical activity or walking and maintaining a healthy weight
  • Hydration: staying well hydrated, as DVT is more likely to develop when the body is dehydrated
  • Avoiding smoking and excessive alcohol consumption
  • Avoiding prolonged immobility: if on bed rest, elevate the feet by at least 5 inches. Move around as soon as possible, and during long flights or road trips, take regular movement breaks and wear compression socks or stockings
  • Compression stockings: wearing compression stockings to improve circulation and prevent leg swelling
  • Contraceptive choices: using progestogen-only contraceptive pills and avoiding those containing oestrogen, or opting for alternative contraceptive methods such as the intrauterine device (IUD)

Summary

DVT is a serious blood clotting condition influenced by blood disorders such as thrombophilia. The prevalence of DVT varies depending on whether thrombophilia is genetic or acquired, as well as individual risk factors such as family history and lifestyle. Prevention strategies, including anticoagulant medication and lifestyle modifications such as regular movement and the use of compression stockings, are essential for reducing the risk of DVT and minimising its complications.

References

  1. Armstrong EM, Bellone JM, Hornsby LB, Treadway S, Phillippe HM. Acquired thrombophilia. J Pharm Pract [Internet]. 2014 [cited 2025 Mar 18];27(3):234–42. Available from: https://journals.sagepub.com/doi/10.1177/0897190014530424
  2. Lipe B, Ornstein DL. Deficiencies of natural anticoagulants, protein C, protein S, and antithrombin. Circulation [Internet]. 2011 [cited 2025 Mar 20];124(14):e365–8. Available from: https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.111.044412
  3. Farmer-Boatwright MK, Roubey RAS. Venous thrombosis in the antiphospholipid syndrome. Arterioscler Thromb Vasc Biol [Internet]. 2009 [cited 2025 Mar 20];29(3):321–5. Available from: https://www.ahajournals.org/doi/10.1161/ATVBAHA.108.182204

Share

Adeline Sever

MSc Experimental Pharmacology and Therapeutics (Neuropharmacology), University College London
BSc Veterinary Bioscience, University of Surrey

Addie is a medical writer with a background in neuropharmacology and biosciences. She has experience in both academic research and science communication, with a strong interest in translating complex medical topics into accessible, engaging content. Addie has worked across various research areas including neuroscience, clinical pharmacology, and animal health. Passionate about clear communication and public health education, she contributes to Klarity with articles that aim to empower readers with medically reviewed, evidence-based information.

arrow-right